ICCM - Icecure Medical

Momentum: Bearish

Recent News

IceCure Medical ( NASDAQ:ICCM ) reported second-quarter 2025 results on Aug. 13, 2025, with revenue declining year-over-year to $1.25 million from $1.75 million for the six months ended June 30, 2025. The company highlighted regulatory progress for its ProSense system in breast cancer, a $10 ...

Neutral

IceCure Medical Ltd. ( ICCM ) Q2 Earnings Surpass Estimates

Zacks Commentary • 1 month ago • score: 0.06

IceCure Medical (ICCM) delivered earnings and revenue surprises of +200.00% and -34.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

IceCure Medical Ltd. ( ICCM ) Reports Q3 Loss, Misses Revenue Estimates

Zacks Commentary • 9 months, 2 weeks ago • score: 0.04

IceCure Medical (ICCM) delivered earnings and revenue surprises of -14.29% and 5.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for the women's health and oncology markets. The company is headquartered in Caesarea, Israel.

52W High

$1.63

52W Low

$0.47

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.48

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.63

EV/Revenue (<3 favorable)

24.29

P/S (TTM) (<3 favorable)

25.37

P/B (<3 favorable)

24.46

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

40.60%

Institutions (25–75% balanced)

0.36%

Shares Outstanding

68,652,000

Float

37,894,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,787,000

Gross Profit (TTM)

1,001,000

EPS (TTM)

-0.27

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-6.45%

ROE (TTM) (>15% strong)

-2.31%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.48

Momentum

Bearish momentum

Value

0.0204

0.0261

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025